Department of Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan (I.K., S.N., A.Y.) and Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Ritsumeikan University, Shiga, Japan (Y.K., T.F.).
Department of Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan (I.K., S.N., A.Y.) and Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Ritsumeikan University, Shiga, Japan (Y.K., T.F.)
Drug Metab Dispos. 2020 Jun;48(6):491-498. doi: 10.1124/dmd.119.088674. Epub 2020 Mar 19.
Breast cancer resistance protein (BCRP) is expressed on the apical membrane of small intestinal epithelial cells and functions as an efflux pump with broad substrate recognition. Therefore, quantitative evaluation of the contribution of BCRP to the intestinal permeability of new chemical entities is very important in drug research and development. In this study, we assessed the BCRP-mediated efflux of several model drugs in Caco-2 cells using WK-X-34 as a dual inhibitor of P-glycoprotein (P-gp) and BCRP and LY335979 as a selective inhibitor of P-gp. The permeability of daidzein was high with an apparent permeability coefficient for apical-to-basal transport ( ) of 20.3 × 10 cm/s. In addition, its efflux ratio () was 1.55, indicating that the contribution of BCRP to its transport is minimal. Estrone-3-sulfate and ciprofloxacin showed relatively higher values (>2.0), whereas their BCRP-related absorptive quotient ( ) was 0.21 and 0.3, respectively. These results indicate that BCRP does not play a major role in regulating the permeability of estrone-3-sulfate and ciprofloxacin in Caco-2 cells. Nitrofurantoin showed a of 1.8 × 10 cm/s, and its was 7.6. However, the was 0.37, suggesting minimal contribution of BCRP to nitrofurantoin transport in Caco-2 cells. In contrast, topotecan, SN-38, and sulfasalazine had low values (0.81, 1.13, and 0.19 × 10 cm/s, respectively), and each was above 0.6, indicating that BCRP significantly contributes to the transport of these compounds in Caco-2 cells. In conclusion, Caco-2 cells are useful to accurately estimate the contribution of BCRP to intestinal drug absorption. SIGNIFICANCE STATEMENT: We performed an in vitro assessment of the contribution of breast cancer resistance protein (BCRP) to the transport of BCRP and/or P-glycoprotein (P-gp) substrates across Caco-2 cell monolayers using absorptive quotient, which has been proposed to represent the contribution of drug efflux transporters to the net efflux. The present study demonstrates that the combined use of a BCRP/P-gp dual inhibitor and a P-gp selective inhibitor is useful to estimate the impact of BCRP and P-gp on the permeability of tested compounds in Caco-2 cells.
乳腺癌耐药蛋白(BCRP)表达于小肠上皮细胞的顶膜上,作为一种具有广泛底物识别的外排泵发挥作用。因此,定量评估 BCRP 对新化学实体的肠道通透性的贡献在药物研发中非常重要。在这项研究中,我们使用 WK-X-34 作为 P-糖蛋白(P-gp)和 BCRP 的双重抑制剂,以及 LY335979 作为 P-gp 的选择性抑制剂,评估了几种模型药物在 Caco-2 细胞中的 BCRP 介导的外排作用。大豆黄素的通透性较高,顶端到基底转运的表观渗透系数( )为 20.3×10cm/s。此外,其外排比( )为 1.55,表明 BCRP 对其转运的贡献最小。雌酮-3-硫酸盐和环丙沙星显示出相对较高的 值(>2.0),而它们的 BCRP 相关吸收商( )分别为 0.21 和 0.3。这些结果表明 BCRP 对 Caco-2 细胞中雌酮-3-硫酸盐和环丙沙星的通透性没有起到主要的调节作用。硝呋太尔的 值为 1.8×10cm/s, 为 7.6。然而, 为 0.37,表明 BCRP 对硝呋太尔在 Caco-2 细胞中的转运贡献很小。相比之下,拓扑替康、SN-38 和柳氮磺胺吡啶的 值较低(分别为 0.81、1.13 和 0.19×10cm/s),且每个 均大于 0.6,表明 BCRP 显著促进了这些化合物在 Caco-2 细胞中的转运。总之,Caco-2 细胞可用于准确估计 BCRP 对肠道药物吸收的贡献。意义陈述:我们使用吸收商对 BCRP 和/或 P-糖蛋白(P-gp)底物在 Caco-2 细胞单层中的转运中 BCRP 的贡献进行了体外评估,该吸收商已被提议代表药物外排转运蛋白对净外排的贡献。本研究表明,联合使用 BCRP/P-gp 双重抑制剂和 P-gp 选择性抑制剂有助于估计 BCRP 和 P-gp 对 Caco-2 细胞中测试化合物通透性的影响。